H101
AXP000003.1 · Oncolytic virus
- Platform
- adenovirus (Ad5, E1B-55kDa and partial E3 deleted)
- Originator
- Shanghai Sunway Biotech
- Sponsor
- Shanghai Sunway Biotech
Names
| Name | Type | Source |
|---|---|---|
| H101 | preferred name, code | curator, ncit |
| Oncorine | brand | ncit |
| Oncolytic Adenovirus H101 | synonym | press |
| rAd5 H101 | synonym | ncit |
| Recombinant Human Adenovirus Type 5 H101 | synonym | ncit |
| Recombinant Human Adenovirus Type 5 Injection ambiguous | synonym | ctgov |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 (H101)
- Replication
- conditionally replicating
- Modifications
- E1B-55kDa deleted; partial E3 deletion
- Route
- intratumoral, intra arterial, intraperitoneal
- Source
- evidence
Cross-references
- NCI Thesaurus
- C107504
- FDA UNII
- QH36X20ODG
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| NMPA | CN | 2005-11 | approved | Oncorine | Nasopharyngeal/head and neck squamous cell carcinoma, by intratumoral injection in combination with cisplatin-based chemotherapy | source |
Clinical trials (21)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06196671 | Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer | Not yet recruiting | Phase 2 | 2026-12-01 | 2028-01-01 | 30 | Pancreatic Cancer |
| NCT07381309 | Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM | Not yet recruiting | Phase 2 | 2026-06-01 | 2028-02-01 | 114 | CRC; Liver Metastasis Colon Cancer |
| NCT07543848 | A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer | Not yet recruiting | Phase 2 | 2026-05-01 | 2028-12-31 | 20 | Rectal Adenocarcinoma; Rectal Neoplasms |
| NCT07398664 | H101 Plus TACE for r/m HNSCC | Recruiting | Phase 2 | 2026-03-02 | 2028-06-15 | 20 | Head and Neck Squamous Cell Carcinoma; Oncolytic Virus; TACE |
| NCT06919848 | Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06) | Not yet recruiting | Phase 2 | 2025-05-01 | 2027-05-01 | 74 | Biliary Tract Cancer (BTC) |
| NCT06253598 | Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma | Not yet recruiting | Phase 2 | 2024-03-30 | 2025-12-30 | 30 | Hepatocellular Carcinoma |
| NCT06031636 | Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma | Unknown | 2023-07-20 | 2026-07-31 | 15 | Malignant Pleural Mesothelioma, Advanced | |
| NCT05872841 | H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis | Unknown | Phase 2 | 2023-06-01 | 2024-12-31 | 38 | Portal Vein Thrombosis; Primary Hepatocellular Carcinoma |
| NCT05823987 | Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05) | Unknown | Phase 2 | 2023-05-16 | 2025-12-30 | 25 | Advanced Biliary Tract Cancer |
| NCT06136910 | Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer | Unknown | Phase 1/2 | 2023-05-09 | 2024-05-09 | 30 | Untreated Advanced Non-small Cell Lung Cancer |
| NCT05675462 | Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma | Unknown | Phase 1 | 2023-03-01 | 2025-12-30 | 25 | Hepatocellular Carcinoma |
| NCT05664139 | Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma | Unknown | Phase 2 | 2023-02 | 2024-12 | 30 | Liver Metastases; Malignant Melanoma |
| NCT05124002 | Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma | Unknown | Phase 4 | 2022-08-01 | 2026-04-01 | 66 | Cholangiocarcinoma, Intrahepatic |
| NCT05303844 | Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites | Unknown | Phase 1 | 2022-04-02 | 2025-03-20 | 25 | Refractory Malignant Ascites |
| NCT05303090 | Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer | Completed | Phase 1 | 2022-03-31 | 2024-04-23 | 56 | Pancreatic Ductal Adenocarcinoma |
| NCT05234905 | H101 Combined With Camrelizumab for Recurrent Cervical Cancer | Unknown | Phase 2 | 2022-03 | 2023-06 | 55 | Camrelizumab; Oncolytic Virotherapy; Uterine Cervical Neoplasms |
| NCT05051696 | Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies | Unknown | Phase 2 | 2021-09-26 | 2024-03-30 | 120 | Genital Neoplasms, Female |
| NCT04771676 | Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites | Completed | Phase 2 | 2021-03-05 | 2023-01-31 | 25 | Refractory Malignant Ascites |
| NCT03780049 | HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B | Unknown | Phase 3 | 2018-10-01 | 2023-10-01 | 304 | Hepatocellular Carcinoma |
| NCT03790059 | Radiofrequency Ablation Combined With Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma. | Unknown | 2016-10 | 2020-09 | 160 | Hepatocellular Carcinoma | |
| NCT02579564 | Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients | Unknown | Phase 3 | 2016-10 | 2018-06 | 134 | Malignant Hydrothorax; Non Small Cell Lung Cancer |
Unconfirmed matches (8)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT07850869 | A Real-World Observational Study of Intratumoral H101 Oncolytic Adenovirus Combined With Immune Checkpoint Inhibitors for Advanced Metastatic Breast Cancer | Recruiting | 2026-09-09 | 2028-02-29 | 15 | Breast Cancer (Locally Advanced or Metastatic) | name in title: H101 | |
| NCT07356791 | Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety | Not yet recruiting | Phase 2 | 2026-02-01 | 2026-12-31 | 18 | Bladder (Urothelial, Transitional Cell) Cancer | intervention named: Recombinant Human Adenovirus Type 5 Injection |
| NCT06685354 | Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study | Unknown | Phase 2 | 2024-11 | 2026-10 | 11 | Hepatocellular Carcinoma (HCC) | name in title: H101 |
| NCT06455046 | Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer | Unknown | Phase 2 | 2023-10-11 | 2025-10-10 | 37 | Cervical Cancer Recurrent | intervention named: Recombinant Human Adenovirus Type 5 Injection |
| NCT05928962 | An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas | Unknown | Phase 1 | 2022-10-27 | 2023-08-01 | 10 | Malignant Melanomas | intervention named: Recombinant Human Adenovirus Type 5 Injection |
| NCT05564897 | Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer | Unknown | Phase 2 | 2022-08-26 | 2024-09-30 | 25 | Bladder Cancer | name in intervention: H101 |
| NCT05113290 | Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment | Unknown | Phase 4 | 2021-12-28 | 2023-12-01 | 66 | Hepatocellular Carcinoma | intervention named: Recombinant Human Adenovirus Type 5 Injection |
| NCT01869088 | TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma | Unknown | Phase 3 | 2013-01 | 2018-01 | 266 | Hepatocellular Carcinoma | intervention named: Recombinant Human Adenovirus Type 5 Injection |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41859855 | The safety and efficacy of recombinant human adenovirus 5 injection (H101) intraperitoneal administration combined with tislelizumab and platinum, fluorouracil-based drugs in the treatment of gastric cancer with peritoneal metastasis: an open-label, single-arm, prospective clinical study protocol. | Future oncology (London, England) | 2026 | name in title: H101 |
| PMID 40667543 | Induction of abscopal effect combining H101 oncolytic virotherapy with tislelizumab in a patient with advanced hepatocellular carcinoma: a case report. | American journal of cancer research | 2025 | name in title: H101 |
| PMID 40812353 | Locoregional Treatment Options for Locally Advanced Intrahepatic Cholangiocarcinoma. | Journal of the National Comprehensive Cancer Network : JNCCN | 2025 | cited by trial NCT05124002 |
| PMID 41357181 | Case report: Local and systemic combination therapy: endoscopic injection of an oncolytic virus with PD-1 inhibitor for an elderly patient with advanced gastrointestinal cancer. | Frontiers in immunology | 2025 | name in abstract: Oncolytic Adenovirus H101 |
| PMID 38659226 | Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study. | Molecular therapy : the journal of the American Society of Gene Therapy | 2024 | cited by trial NCT04771676 |
| PMID 38978969 | A Case Report of Pathologically Complete Response of a Huge Lymph Node Metastasis of Colorectal Cancer After Treatment with Intratumoral Oncolytic Virus H101 and Capecitabine. | ImmunoTargets and therapy | 2024 | name in title: H101 |
| PMID 39588306 | Reverse resistance to immune checkpoint inhibitor in a patient with recurrent cardia cancer by intratumoral injection of recombinant human adenovirus type 5: a case report and literature review. | Frontiers in oncology | 2024 | name in abstract: Recombinant Human Adenovirus Type 5 H101 |
| PMID 37675621 | Effectiveness and safety of human type 5 recombinant adenovirus (H101) in malignant tumor with malignant pleural effusion and ascites: A multicenter, observational, real-world study. | Thoracic cancer | 2023 | name in title: H101 |
| PMID 35399603 | Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response. | Molecular therapy oncolytics | 2022 | cited by trial NCT06196671 |
| PMID 33760389 | Recombinant human adenovirus type 5 (Oncorine) reverses resistance to immune checkpoint inhibitor in a patient with recurrent non-small cell lung cancer: A case report. | Thoracic cancer | 2021 | name in title: Oncorine |
| PMID 35071441 | Successful treatment of a 19-year-old patient with locally advanced clear cell adenocarcinoma of the uterine cervix using recombinant human adenovirus type 5 (Oncorine) combined with chemoradiotherapy: a case report. | Annals of translational medicine | 2021 | name in title: Oncorine |
| PMID 32067509 | Combination therapy with oncolytic viruses and immune checkpoint inhibitors. | Expert opinion on biological therapy | 2020 | cited by trial NCT06196671 |
| PMID 21633603 | Transarterial injection of H101 in combination with chemoembolization overcomes recurrent hepatocellular carcinoma. | World journal of gastroenterology | 2011 | name in title: H101 |
| PMID 15534920 | Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. | World journal of gastroenterology | 2004 | name in title: H101 |
| PMID 15601557 | [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]. | Ai zheng = Aizheng = Chinese journal of cancer | 2004 | name in title: H101 |
| PMID 14693057 | [Phase II clinical study of intratumoral H101, an E1B deleted adenovirus, in combination with chemotherapy in patients with cancer]. | Ai zheng = Aizheng = Chinese journal of cancer | 2003 | name in title: H101 |
Unconfirmed matches (3)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42022327 | Case Report: Integration of intratumoral oncolytic adenovirus with total neoadjuvant therapy in metachronous locally advanced rectal cancer. | Frontiers in oncology | 2026 | name in abstract: H101 |
| PMID 40661951 | Overcoming immune resistance in advanced esophageal squamous cell carcinoma with recombinant human adenovirus type 5 by impacting the immune microenvironment: a case report. | Frontiers in immunology | 2025 | name in abstract: H101 |
| PMID 8226457 | Changes in hormonal concentrations after different heavy-resistance exercise protocols in women. | Journal of applied physiology (Bethesda, Md. : 1985) | 1993 | name in abstract: H101 |
Other papers
Preclinical studies, reviews and other papers that name it, newest 100 shown.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40329730 | Talimogene Laherparepvec (T-VEC): Expanding Horizons in Oncolytic Viral Therapy Across Multiple Cancer Types. | Anti-cancer agents in medicinal chemistry | 2026 | name in abstract: Oncorine |
| PMID 41675687 | Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery. | Molecular therapy. Oncology | 2026 | name in abstract: Oncorine |
| PMID 41953007 | Recombinant human adenovirus type 5 synergizes with anti-PD-L1 antibody to promote anti-hepatocellular carcinoma effects through multilevel remodeling of the immune microenvironment. | Frontiers in immunology | 2026 | name in abstract: Recombinant Human Adenovirus Type 5 H101 |
| PMID 42000628 | Oncolytic human adenovirus 5 (H101) modulates cell cycle progression in HPV16-positive tumors. | Biochemical and biophysical research communications | 2026 | name in title: H101 |
| PMID 42161529 | PRXL2B facilitates the progression of hepatocellular carcinoma and the therapeutic efficacy of oncolytic adenovirus H101 through the PI3K/AKT/PD-L1 axis. | Bioscience trends | 2026 | name in title: Oncolytic Adenovirus H101 |
| PMID 42216079 | Recent advances in oncolytic virotherapy: insights from clinical trials and combination treatment strategies. | Virology journal | 2026 | name in abstract: Oncorine |
| PMID 42528584 | Short-term efficacy and safety of recombinant human adenovirus type 5 combined with PD-1 immune checkpoint inhibitors and SOX regimen in neoadjuvant therapy of locally advanced gastric cancer: a retrospective study. | Frontiers in oncology | 2026 | name in abstract: Recombinant Human Adenovirus Type 5 H101 |
| PMID 40170848 | Enhancing pancreatic cancer treatment: the role of H101 oncolytic virus in irreversible electroporation. | Frontiers in immunology | 2025 | name in title: H101 |
| PMID 40296909 | Oncolytic adenovirus H101 enhances the anti-tumor effects of PD-1 blockade via CD47 downregulation in tumor cells. | Oncology research | 2025 | name in title: Oncolytic Adenovirus H101 |
| PMID 40881284 | Oncolytic viruses in head and neck cancers: clinical applications and therapeutic potential. | Frontiers in microbiology | 2025 | name in abstract: Oncorine |
| PMID 41049859 | The combination treatment of oncolytic adenovirus H101 with transcatheter arterial embolization sequential thermal ablation for hepatocellular carcinoma: a retrospective study. | Frontiers in oncology | 2025 | name in title: Oncolytic Adenovirus H101 |
| PMID 41403317 | Recombinant human type-5 adenovirus (H101) combined with radiofrequency ablation versus traditional radiofrequency ablation for hepatocellular carcinoma ≤ 3 cm: a phase III randomized controlled trial. | International journal of surgery (London, England) | 2025 | name in title: H101 |
| PMID 38325225 | The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study. | ESMO open | 2024 | name in title: Oncolytic Adenovirus H101 |
| PMID 38576614 | New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy. | Frontiers in immunology | 2024 | name in abstract: Oncorine |
| PMID 38782895 | Induced dual-target rebalance simultaneously enhances efficient therapeutical efficacy in tumors. | Cell death discovery | 2024 | name in abstract: Oncolytic Adenovirus H101 |
| PMID 39238337 | Correction to "The Oncolytic Virus H101 Combined with Gnaq Sirna-Mediated Knockdown Reduces Uveal Melanoma Cell Viability". | Journal of cellular biochemistry | 2024 | name in title: H101 |
| PMID 36299168 | Oncolytic virus preclinical toxicology studies. | Journal of applied toxicology : JAT | 2023 | name in abstract: Oncorine |
| PMID 37065938 | Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health. | Translational medicine communications | 2023 | name in abstract: Oncorine |
| PMID 37208018 | Intratumoral injection of oncolytic virus (H101) in combination with concurrent chemoradiotherapy for locally advanced cervical cancer. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2023 | name in title: H101 |
| PMID 38046281 | Recombinant Human Adenovirus Type 5 (H101) Intra-Tumor Therapy in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer: Genomic Profiling Relating to Clinical Efficacy. | Drug design, development and therapy | 2023 | name in title: Recombinant Human Adenovirus Type 5 H101 |
| PMID 38152740 | Retracted: Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis. | Applied bionics and biomechanics | 2023 | name in title: H101 |
| PMID 34958003 | Ubiquitination and degradation of MGMT by TRIM72 increases the sensitivity of uveal melanoma cells to Dacarbazine treatment. | Cancer biomarkers : section A of Disease markers | 2022 | name in abstract: Oncolytic Adenovirus H101 |
| PMID 35273918 | Corrigendum: A Recombinant Human Adenovirus Type 5 (H101) Combined With Chemotherapy for Advanced Gastric Carcinoma: A Retrospective Cohort Study. | Frontiers in oncology | 2022 | name in title: Recombinant Human Adenovirus Type 5 H101 |
| PMID 35574359 | Efficacy and Safety of Recombinant Human Adenovirus Type 5 (H101) in Persistent, Recurrent, or Metastatic Gynecologic Malignancies: A Retrospective Study. | Frontiers in oncology | 2022 | name in title: Recombinant Human Adenovirus Type 5 H101 |
| PMID 35756634 | Role of Adenoviruses in Cancer Therapy. | Frontiers in oncology | 2022 | name in abstract: Oncorine |
| PMID 35762456 | Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer. | Cancer medicine | 2022 | name in title: Oncolytic Adenovirus H101 |
| PMID 36091626 | Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis. | Applied bionics and biomechanics | 2022 | name in title: H101 |
| PMID 33687882 | Oncolytic Adenovirus H101 Synergizes with Radiation in Cervical Cancer Cells. | Current cancer drug targets | 2021 | name in title: Oncolytic Adenovirus H101 |
| PMID 34332576 | A review on the advances and challenges of immunotherapy for head and neck cancer. | Cancer cell international | 2021 | name in abstract: Oncorine |
| PMID 34956877 | A Recombinant Human Adenovirus Type 5 (H101) Combined With Chemotherapy for Advanced Gastric Carcinoma: A Retrospective Cohort Study. | Frontiers in oncology | 2021 | name in title: Recombinant Human Adenovirus Type 5 H101 |
| PMID 35116288 | The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis. | Translational cancer research | 2021 | name in abstract: Oncolytic Adenovirus H101 |
| PMID 32163385 | [Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer]. | Molekuliarnaia biologiia | 2020 | name in abstract: Oncorine |
| PMID 33376352 | Overexpression of LncRNA SNHG1 Were Suitable for Oncolytic Adenoviruse H101 Therapy in Oral Squamous-Cell Carcinoma. | OncoTargets and therapy | 2020 | name in title: H101 |
| PMID 30320917 | The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability. | Journal of cellular biochemistry | 2019 | name in title: H101 |
| PMID 29189159 | Oncorine, the World First Oncolytic Virus Medicine and its Update in China. | Current cancer drug targets | 2018 | name in title: Oncorine |
| PMID 29284308 | Fighting Cancer with Viruses: Oncolytic Virus Therapy in China. | Human gene therapy | 2018 | name in abstract: Oncorine |
| PMID 29334764 | Development of Gene Therapeutics for Head and Neck Cancer in China: From Bench to Bedside. | Human gene therapy | 2018 | name in abstract: Oncorine |
| PMID 28278076 | Adenovirus-based strategies enhance antitumor capability through p53-mediated downregulation of MGMT in uveal melanoma. | Cancer biology & therapy | 2017 | name in abstract: Oncolytic Adenovirus H101 |
| PMID 28355305 | Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101. | PloS one | 2017 | name in title: H101 |
| PMID 28599488 | Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo. | Oncology letters | 2017 | name in title: Oncolytic Adenovirus H101 |
| PMID 28664952 | Quantifying ultrafast charge carrier injection from methylammonium lead iodide into the hole-transport material H101 and mesoporous TiO2 using Vis-NIR transient absorption. | Physical chemistry chemical physics : PCCP | 2017 | name in title: H101 |
| PMID 28728568 | Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study. | Chinese journal of cancer | 2017 | name in title: Recombinant Human Adenovirus Type 5 H101 |
| PMID 28782065 | Photoinduced dynamics of the hole-transport material H101 in organic solvents and on mesoporous Al2O3 and TiO2 thin films. | Physical chemistry chemical physics : PCCP | 2017 | name in title: H101 |
| PMID 26081001 | The antitumor effects of oncolytic adenovirus H101 against lung cancer. | International journal of oncology | 2015 | name in title: Oncolytic Adenovirus H101 |
| PMID 26259388 | Strategies used in the clinical trials of gene therapy for cancer. | Journal of experimental therapeutics & oncology | 2015 | name in abstract: Oncorine |
| PMID 26470869 | Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC). | BMC cancer | 2015 | name in title: H101 |
| PMID 25468274 | DA virus mutant H101 has altered CNS pathogenesis and causes immunosuppression. | Journal of neuroimmunology | 2014 | name in title: H101 |
| PMID 21740357 | Clinical development of oncolytic viruses in China. | Current pharmaceutical biotechnology | 2012 | name in abstract: Oncorine |
| PMID 22843987 | Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines. | The British journal of ophthalmology | 2012 | name in title: Oncolytic Adenovirus H101 |
| PMID 22937170 | Therapeutic efficacy by targeting correction of Notch1-induced aberrants in uveal tumors. | PloS one | 2012 | name in abstract: Oncolytic Adenovirus H101 |
| PMID 22992863 | Coxsackievirus and adenovirus receptor promotes antitumor activity of oncolytic adenovirus H101 in esophageal cancer. | International journal of molecular medicine | 2012 | name in title: Oncolytic Adenovirus H101 |
| PMID 23021247 | Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. | Advances in cancer research | 2012 | name in abstract: Oncorine |
| PMID 24236929 | Oncolytic virus therapies. | Pharmaceutical patent analyst | 2012 | name in abstract: Oncorine |
| PMID 22335946 | [Effect of CEA gene regulation on the anti-tumor activity of oncolytic adenovirus H101 to esophageal carcinoma]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] | 2011 | name in title: Oncolytic Adenovirus H101 |
| PMID 20007825 | Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101. | Investigative ophthalmology & visual science | 2010 | name in title: Oncolytic Adenovirus H101 |
Unconfirmed matches (45)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41268599 | [Expression of Concern] Gene therapy for human colorectal cancer cell lines with recombinant adenovirus 5 based on loss of the insulin‑like growth factor 2 imprinting. | International journal of oncology | 2026 | name in abstract: H101 |
| PMID 41827827 | Oncolytic Viruses in Cancer Immunotherapy: From Molecular Engineering to Clinical Translation. | Cells | 2026 | name in abstract: H101 |
| PMID 42025901 | Efficacy of oncolytic viruses (OVs) in malignant tumor therapy: a review on its therapeutic aspects. | Clinica chimica acta; international journal of clinical chemistry | 2026 | name in abstract: H101 |
| PMID 42909267 | Liver-resident cellular determinants of oncolytic virotherapy in hepatocellular carcinoma: viral susceptibility and spatial immune remodeling. | Frontiers in cell and developmental biology | 2026 | name in abstract: H101 |
| PMID 40948961 | Live culture-based qPCR screening of Taq DNA polymerase variants for resistance to PCR inhibitors. | Frontiers in bioengineering and biotechnology | 2025 | name in abstract: H101 |
| PMID 41040530 | Recombinant human adenovirus type 5 administration for the treatment of malignant ascites or pleural effusion in cancer patients: a meta-analysis. | Frontiers in oncology | 2025 | name in abstract: H101 |
| PMID 38180875 | The Arabidopsis SR45 splicing factor bridges the splicing machinery and the exon-exon junction complex. | Journal of experimental botany | 2024 | name in abstract: H101 |
| PMID 39030309 | Recombinant human adenovirus type 5 promotes anti-tumor immunity via inducing pyroptosis in tumor endothelial cells. | Acta pharmacologica Sinica | 2024 | name in abstract: H101 |
| PMID 39227421 | Balancing volumetric and gravimetric capacity for hydrogen in supramolecular crystals. | Nature chemistry | 2024 | name in abstract: H101 |
| PMID 39293238 | Breaking Barriers: Animal viruses as oncolytic and immunotherapeutic agents for human cancers. | Virology | 2024 | name in abstract: H101 |
| PMID 37214817 | Comparing FRET pairs that report on intersubunit rotation in bacterial ribosomes. | bioRxiv : the preprint server for biology | 2023 | name in abstract: H101 |
| PMID 37348753 | Comparing FRET Pairs that Report on Intersubunit Rotation in Bacterial Ribosomes. | Journal of molecular biology | 2023 | name in abstract: H101 |
| PMID 37620054 | Isolation and genome sequencing of a novel lytic Pseudoalteromonas phage SL20. | Marine genomics | 2023 | name in abstract: H101 |
| PMID 37801472 | Partial spontaneous intersubunit rotations in pretranslocation ribosomes. | Proceedings of the National Academy of Sciences of the United States of America | 2023 | name in abstract: H101 |
| PMID 34225616 | H101G Mutation in Rat Lens αB-Crystallin Alters Chaperone Activity and Divalent Metal Ion Binding. | Current pharmaceutical biotechnology | 2022 | name in abstract: H101 |
| PMID 35027480 | Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo. | Molecular cancer therapeutics | 2022 | name in abstract: H101 |
| PMID 35131956 | Discovery of Chitin Deacetylase Inhibitors through Structure-Based Virtual Screening and Biological Assays. | Journal of microbiology and biotechnology | 2022 | name in abstract: H101 |
| PMID 35715049 | Identification and antioxidant capacity of 4-hydroxyphenylpyruvate dioxygenase (HPPD), a new favored herbicide target, in Apis cerana cerana. | Pesticide biochemistry and physiology | 2022 | name in abstract: H101 |
| PMID 35836877 | Advances in the clinical development of oncolytic viruses. | American journal of translational research | 2022 | name in abstract: H101 |
| PMID 35425109 | Exploration of conjugated π-bridge units in N,N-bis(4-methoxyphenyl)naphthalen-2-amine derivative-based hole transporting materials for perovskite solar cell applications: a DFT and experimental investigation. | RSC advances | 2021 | name in abstract: H101 |
| PMID 33182528 | A Tumor-Targeted Replicating Oncolytic Adenovirus Ad-TD-nsIL12 as a Promising Therapeutic Agent for Human Esophageal Squamous Cell Carcinoma. | Cells | 2020 | name in abstract: H101 |
| PMID 33281788 | Altering Intracellular Localization of the RNA Interference Factors by Influenza A Virus Non-structural Protein 1. | Frontiers in microbiology | 2020 | name in abstract: H101 |
| PMID 31144549 | Achieving systemic delivery of oncolytic viruses. | Expert opinion on drug delivery | 2019 | name in abstract: H101 |
| PMID 31933185 | Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma. | Pharmaceutical medicine | 2019 | name in abstract: H101 |
| PMID 29435900 | Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis. | Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract | 2018 | name in abstract: H101 |
| PMID 28741149 | The role of peripheral interleukin-6 in the development of acute seizures following virus encephalitis. | Journal of neurovirology | 2017 | name in abstract: H101 |
| PMID 29302257 | ELISA for Quantitative Determination of Hepatitis B Virus Surface Antigen. | Immune network | 2017 | name in abstract: H101 |
| PMID 27391605 | Beyond Oncolytics: E1B55K-Deleted Adenovirus as a Vaccine Delivery Vector. | PloS one | 2016 | name in abstract: H101 |
| PMID 27717041 | Effects of Gabra2 Point Mutations on Alcohol Intake: Increased Binge-Like and Blunted Chronic Drinking by Mice. | Alcoholism, clinical and experimental research | 2016 | name in abstract: H101 |
| PMID 25652289 | Identification and analysis of icCu/Zn-SOD, Mn-SOD and ecCu/Zn-SOD in superoxide dismutase multigene family of Pseudosciaena crocea. | Fish & shellfish immunology | 2015 | name in abstract: H101 |
| PMID 26561828 | Oncolytic Replication of E1b-Deleted Adenoviruses. | Viruses | 2015 | name in abstract: H101 |
| PMID 24634079 | A simple 3,4-ethylenedioxythiophene based hole-transporting material for perovskite solar cells. | Angewandte Chemie (International ed. in English) | 2014 | name in abstract: H101 |
| PMID 25364261 | Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. | OncoTargets and therapy | 2014 | name in abstract: H101 |
| PMID 23308109 | A unified model of the GABA(A) receptor comprising agonist and benzodiazepine binding sites. | PloS one | 2013 | name in abstract: H101 |
| PMID 24269822 | An oncolytic adenovirus enhances antiangiogenic and antitumoral effects of a replication-deficient adenovirus encoding endostatin by rescuing its selective replication in nasopharyngeal carcinoma cells. | Biochemical and biophysical research communications | 2013 | name in abstract: H101 |
| PMID 22280899 | Microbacterium marinum sp. nov., isolated from deep-sea water. | Systematic and applied microbiology | 2012 | name in abstract: H101 |
| PMID 22336909 | Combination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle block. | Cancer biology & therapy | 2012 | name in abstract: H101 |
| PMID 22880939 | Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets. | Expert opinion on therapeutic targets | 2012 | name in abstract: H101 |
| PMID 23071601 | A novel anticancer therapy that simultaneously targets aberrant p53 and Notch activities in tumors. | PloS one | 2012 | name in abstract: H101 |
| PMID 23240001 | Crystal structure of two anti-porphyrin antibodies with peroxidase activity. | PloS one | 2012 | name in abstract: H101 |
| PMID 21630357 | A missense mutation in CLIC2 associated with intellectual disability is predicted by in silico modeling to affect protein stability and dynamics. | Proteins | 2011 | name in abstract: H101 |
| PMID 21680509 | Lack of correlation of central nervous system inflammation and neuropathology with the development of seizures following acute virus infection. | Journal of virology | 2011 | name in abstract: H101 |
| PMID 22295575 | [Binding of human ribosomal protein S13 to the central domain of 18S rRNA]. | Molekuliarnaia biologiia | 2011 | name in abstract: H101 |
| PMID 20487541 | Increased plasma membrane cholesterol in cystic fibrosis cells correlates with CFTR genotype and depends on de novo cholesterol synthesis. | Respiratory research | 2010 | name in abstract: H101 |
| PMID 19018252 | Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors. | Molecular therapy : the journal of the American Society of Gene Therapy | 2009 | name in abstract: H101 |
NIH grants
No confirmed grants yet.
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R56CA102053 | Spread of Replicating Adenovirus in Solid Tumors | NEW YORK UNIVERSITY SCHOOL OF MEDICINE | HAY, JOHN G. | 2009–2009 | name in abstract: H101 |
Notes
Approved in China 2005 as Oncorine; no INN, so the code H101 is the preferred name. Construct description not re-verified from a primary source.
How to cite
H101 (AXP000003.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000003.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.